Kelun-Biotech / 科伦博泰

Kelun-Biotech / 科伦博泰 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as a Chinese ADC company example involved in large MNC licensing. The episode uses the company to show both sides of ADC enthusiasm: large deals can validate Chinese engineering capability, but some licensed assets may later be terminated or repriced.

The page is source-scoped around ADC Engineering Optimization. It does not attempt to evaluate Kelun-Biotech’s full portfolio or current business status.

Connections

• ADC Engineering Optimization - main technical field associated with the source mention.
• Biotech License-Out Arbitrage and China Biotech Asset Repricing - transaction context.
• Dual-Payload ADC - later ADC direction discussed in the same episode.